
Thursday, September 26, 2024 10:01:26 AM
Volume: | 53,822 |
Day Range: | 0.9151 - 1.04 |
Bid: | |
Ask: | |
Last Trade Time: | 4:10:00 PM EDT |
Total Trades: | 292 |
Recent KAPA News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2025 12:05:18 PM
- Kairos Pharma Presents Preclinical Data on its Investigational Compounds KROS 101 and KROS 401 Further Supporting Both Compounds’ Potential as Therapeutics for Melanoma and Glioblastoma • Business Wire • 02/26/2025 12:00:00 PM
- Kairos Pharma Announces New Department of Defense Funding for Research of ENV205 • Business Wire • 02/18/2025 01:30:00 PM
- Kairos Pharma Adds Huntsman Cancer Institute for Phase 2 ENV105 Clinical Trial • Business Wire • 02/11/2025 01:30:00 PM
- Form DEF 14C - Other definitive information statements • Edgar (US Regulatory) • 02/10/2025 09:45:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/06/2025 02:00:23 PM
- Kairos Pharma Oral Presentation on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference Supports the Compound’s Potential as a Therapeutic for Melanoma and Glioblastoma • Business Wire • 02/06/2025 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 02/05/2025 11:15:31 AM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/05/2025 05:15:08 AM
- Form PRE 14C - Other preliminary information statements • Edgar (US Regulatory) • 01/29/2025 12:22:27 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 01/29/2025 11:39:57 AM
- Kairos Pharma to Present Short Talk on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference February 5, 2024 • Business Wire • 01/28/2025 01:15:00 PM
- Kairos Pharma Provides Business Update and Outlook into 2025 • Business Wire • 01/21/2025 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/17/2025 10:20:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/14/2025 02:41:01 PM
- Kairos Pharma to Present at the Lytham Partners Investor Healthcare Summit • Business Wire • 01/07/2025 01:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/13/2024 09:10:25 PM
- Kairos Pharma Adds City of Hope Cancer Center for Phase 2 ENV105 Clinical Trial • Business Wire • 12/03/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/19/2024 01:48:35 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2024 07:19:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/10/2024 09:30:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/04/2024 09:29:56 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 09/27/2024 09:17:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/27/2024 09:10:33 PM
The Crypto Company Expands Leadership Team With Experienced Financial and Blockchain Professionals • CRCW • Mar 13, 2025 9:23 AM
ConnectM Announces $10 Million Share Repurchase Program • CNTM • Mar 13, 2025 9:13 AM
Sigyn CEO Note: An Emerging New Industry, 15 Years in the Making • SIGY • Mar 12, 2025 9:41 AM
$PYPD - PolyPid Hits Major Milestone: Completes Trial Enrollment, Poised for Potential Breakthrough in $10 Billion Surgical Infection Market • NRXS • Mar 11, 2025 10:30 AM
UC Asset Acquired $3M Cannabis Property via Non-Cash Deal • UCASU • Mar 11, 2025 9:53 AM
1606 Corp. Signs LOI to Be Acquired by Private Group Seeking to Enter the Public Markets and Utilize AI Technologies for Potential Uplisting • CBDW • Mar 11, 2025 8:30 AM